[go: up one dir, main page]

MX346203B - Formas de dosificacion retentivas gastricas para liberacion prolongada de acamprosato en el tracto gastrointestinal superior. - Google Patents

Formas de dosificacion retentivas gastricas para liberacion prolongada de acamprosato en el tracto gastrointestinal superior.

Info

Publication number
MX346203B
MX346203B MX2013003556A MX2013003556A MX346203B MX 346203 B MX346203 B MX 346203B MX 2013003556 A MX2013003556 A MX 2013003556A MX 2013003556 A MX2013003556 A MX 2013003556A MX 346203 B MX346203 B MX 346203B
Authority
MX
Mexico
Prior art keywords
dosage forms
disease
acamprosate
gastric retentive
gastrointestinal tract
Prior art date
Application number
MX2013003556A
Other languages
English (en)
Other versions
MX2013003556A (es
Inventor
Berner Bret
Chen Cuiping
Original Assignee
Depomed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Depomed Inc filed Critical Depomed Inc
Publication of MX2013003556A publication Critical patent/MX2013003556A/es
Publication of MX346203B publication Critical patent/MX346203B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Addiction (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención describe formas de dosificación retentivas gástricas para liberación sostenida de acamprosato que pueden permitir dosificación una vez al día o dos veces al día para tratamiento tanto agudo como de larga duración de un trastorno que incluye dependencia del alcohol, zumbido de oídos, apnea del sueño, mal de Parkinson, disquinesias inducidas por levadopa en mal de Parkinson, enfermedad de Alzheimer, enfermedad de Huntington, esclerosis lateral amiotrófica, depresión de diseminación cortical, migraña, esquizofrenia, ansiedad, disquinesia tardía, espasticidad, esclerosis múltiple, varios tipos de dolor, o comer compulsivamente. También se describen métodos de tratamiento que usan las formas de dosificación y métodos para hacer las formas de dosificación.
MX2013003556A 2010-09-28 2011-09-28 Formas de dosificacion retentivas gastricas para liberacion prolongada de acamprosato en el tracto gastrointestinal superior. MX346203B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38736810P 2010-09-28 2010-09-28
PCT/US2011/053769 WO2012050922A2 (en) 2010-09-28 2011-09-28 Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract

Publications (2)

Publication Number Publication Date
MX2013003556A MX2013003556A (es) 2013-06-28
MX346203B true MX346203B (es) 2017-03-09

Family

ID=45871269

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013003556A MX346203B (es) 2010-09-28 2011-09-28 Formas de dosificacion retentivas gastricas para liberacion prolongada de acamprosato en el tracto gastrointestinal superior.

Country Status (5)

Country Link
US (3) US9000046B2 (es)
EP (1) EP2621487B1 (es)
CA (1) CA2850468C (es)
MX (1) MX346203B (es)
WO (1) WO2012050922A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2850468C (en) 2010-09-28 2019-08-13 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
US20130143867A1 (en) * 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
AU2012345659B2 (en) * 2011-12-02 2017-09-28 Synchroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
GB201303649D0 (en) 2013-03-01 2013-04-17 Univ Aston Hydrogen sulphide compounds
WO2014197744A1 (en) * 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US10357469B2 (en) 2015-02-18 2019-07-23 Aston University Diagnostic assay and treatment for preeclampsia
JP7026347B2 (ja) * 2015-05-04 2022-02-28 コンフルーエンス ファーマシューティカルズ，エルエルシー アカンプロサートのスプリンクル製剤
CN105372401B (zh) * 2015-12-17 2017-06-23 中国人民解放军新疆军区联勤部药品仪器检验所 仿制药品质量的检测方法
EP3269361A1 (en) * 2016-07-14 2018-01-17 Omya International AG Dosage form
WO2018175648A1 (en) * 2017-03-21 2018-09-27 Bioduro, Llc Gastrointestinal-protective formulations for oral delivery of proteins and peptides
EP3624788A4 (en) * 2017-05-17 2021-03-03 Confluence Pharmaceuticals, LLC FORMULATIONS OF HOMOTAURINS AND THEIR SALTS
CN112004520B (zh) 2017-12-18 2024-08-23 特瑞斯制药公司 包括具有触发脉冲药物释放的胃内滞留筏形成系统的调节释放药物粉末组合物
WO2019126214A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release
WO2019126215A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
CA3097737A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
US20210196627A1 (en) * 2018-08-15 2021-07-01 Lyndra, Inc. Systems for enteric delivery of therapeutic agents
EP3968980A1 (en) 2019-05-14 2022-03-23 Clexio Biosciences Ltd. Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
WO2022195476A1 (en) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Gastroretentive devices for assessment of intragastric conditions
CN121038779A (zh) 2023-02-03 2025-11-28 特瑞斯制药公司 每晚一次的低钠羟丁酸盐组合物
WO2025163673A1 (en) * 2024-01-29 2025-08-07 Micro Labs Limited Dose-dumping resistant tablets of acamprosate calcium

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4014334A (en) 1976-02-02 1977-03-29 Alza Corporation Laminated osmotic system for dispensing beneficial agent
US4058122A (en) 1976-02-02 1977-11-15 Alza Corporation Osmotic system with laminated wall formed of different materials
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4940465A (en) 1987-05-27 1990-07-10 Felix Theeuwes Dispenser comprising displaceable matrix with solid state properties
US4892778A (en) 1987-05-27 1990-01-09 Alza Corporation Juxtaposed laminated arrangement
IL87710A (en) 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
AU721276B2 (en) 1995-04-04 2000-06-29 Wound Healing Of Oklahoma Cancer treatment by photodynamic therapy, in combination with an immunoadjuvant
US5866585A (en) 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
US6057373A (en) 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
WO1998055107A1 (en) 1997-06-06 1998-12-10 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
US6391922B1 (en) 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
US5952389A (en) 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
US6294583B1 (en) 1998-01-13 2001-09-25 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
US6159944A (en) 1998-02-27 2000-12-12 Synchroneuron, Llc Method for treating painful conditions of the anal region and compositions therefor
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
EP1126827A2 (en) 1998-11-02 2001-08-29 Alza Corporation Controlled delivery of active agents
IL149421A0 (en) 1999-11-02 2002-11-10 Depomed Inc Pharmaceutical compositions containing fed mode inducing agents
EP1251832B1 (en) 2000-02-04 2006-09-27 Depomed, Inc. Shell-and-core dosage form approaching zero-order drug release
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
DE10129265A1 (de) 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
DE102007009242A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit magensaftresistenter Wirkstoff-Matix
AU2008282900B2 (en) 2007-07-27 2014-05-22 Depomed, Inc. Pulsatile gastric retentive dosage forms
CA2850468C (en) 2010-09-28 2019-08-13 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract

Also Published As

Publication number Publication date
US20150164832A1 (en) 2015-06-18
WO2012050922A3 (en) 2012-08-02
US9000046B2 (en) 2015-04-07
MX2013003556A (es) 2013-06-28
EP2621487B1 (en) 2017-05-03
EP2621487A4 (en) 2014-05-14
CA2850468C (en) 2019-08-13
US9801816B2 (en) 2017-10-31
US20160184224A1 (en) 2016-06-30
US9301934B2 (en) 2016-04-05
CA2850468A1 (en) 2012-04-19
WO2012050922A2 (en) 2012-04-19
EP2621487A2 (en) 2013-08-07
US20120077878A1 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
MX346203B (es) Formas de dosificacion retentivas gastricas para liberacion prolongada de acamprosato en el tracto gastrointestinal superior.
GB2443287B (en) Methods, compositions and formulations for the treatment of thyroid eye disease
CY1112320T1 (el) Τιτλοδοτηση της ταπενταδολης
MX2013006591A (es) Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
MY158504A (en) Fatty acid niacin conjugates and their uses
JO3076B1 (ar) نظم العلاج المناعي المعتمد على حالة apoe
EP2475358A4 (en) COMPOSITION WITH ANIONIC CORE FOR THE RELEASE OF THERAPEUTICS AND METHOD FOR THE PRODUCTION AND USE THEREOF
BRPI0911874A2 (pt) composições combinadas para o tratamento da doença de alzheimer e doenças relacionadas com zonisamida e acamprosato
PL2262476T3 (pl) Dostarczanie leku do przedniego i tylnego odcinka oka z użyciem kropli do oczu
BRPI0817271A2 (pt) Método de tratamento da doença de parkinson e outros distúrbios relacionados
EP2094281A4 (en) USE OF LIPID CONJUGATES IN THE TREATMENT OF DISEASES OR OCULAR DISORDERS
DK2276485T3 (da) Anvendelse af epothilon d i behandling af tau-associerede sygdomme,herunder alzheimers sygdom
MY153408A (en) Novel methods
EP2306824A4 (en) IONTOPHORETIC DELIVERY OF CURCUMINE AND CURCUMINANALOGUE FOR THE TREATMENT OF MORBUS ALZHEIMER
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
WO2010105035A9 (en) Prevention, treatment, and diagnosis of alzheimer's disease through electromagnetic field exposure
ZA201000959B (en) The use of extracts or materials extracted from Piper cubeba L. as an effective component in a drug for the treatment of cancer diseases
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease
WO2010085799A9 (en) Compositions and method for the treatment of parkinson's disease
EP2517704A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATING PARKINSON'S DISEASE AND METHOD OF MAKING SAME
EA200900923A1 (ru) Применение нейропротективных соединений в получении лекарственных средств, предназначенных для лечения нейродегенеративных заболеваний
FR2918281B1 (fr) Medicament pour le traitement de la maladie de parkinson.
WO2012040444A3 (en) Treatment of patients with incipient alzheimer's disease
WO2009071725A3 (es) Utilización de valproato para el tratamiento del miedo y la fobia en sujetos con la enfermedad de alzheimer
GB201101088D0 (en) L-carnosine and cinnamon extract for the treatment of Alzheimer's Disease

Legal Events

Date Code Title Description
FG Grant or registration